Dapagliflozin ' s Cost-effectiveness ' Intermediate ' for HFrEF Dapagliflozin ' s Cost-effectiveness ' Intermediate ' for HFrEF
New analysis shows that despite reducing CV death in heart failure with reduced ejection fraction, the current cost of dapagliflozin makes it only an ' intermediate ' value in terms of cost-effectiveness.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Health | Heart | Heart Failure